Loading...
XSHG688366
Market cap1.66bUSD
Jan 09, Last price  
56.53
1D
-1.69%
1Q
-17.62%
IPO
-56.75%
Name

Shanghai Haohai Biological Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:688366 chart
P/E
P/S
EPS
0.81
Div Yield, %
0.25%
Shrs. gr., 5y
15.87%
Rev. gr., 5y
11.26%
Revenues
2.63b
+25.27%
303,065,000401,088,000515,940,000663,917,000851,157,0001,344,856,0001,545,824,0001,595,498,0001,324,427,0001,750,116,0002,103,438,0002,634,910,000
Net income
416m
+130.58%
113,942,000141,521,000183,582,000273,474,000305,052,000372,415,000414,540,000370,779,000230,072,000352,234,000180,470,000416,121,000
CFO
634m
+174.30%
118,420,000146,906,000141,993,000268,511,000254,485,000343,059,000391,284,000348,911,000262,073,000342,286,000231,296,000634,450,000
Dividend
Oct 10, 20240.4 /sh
Earnings
May 29, 2025

Profile

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
IPO date
Apr 30, 2015
Employees
2,123
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,634,910
25.27%
2,103,438
20.19%
Cost of revenue
2,238,353
1,923,543
Unusual Expense (Income)
NOPBT
396,557
179,895
NOPBT Margin
15.05%
8.55%
Operating Taxes
95,991
45,395
Tax Rate
24.21%
25.23%
NOPAT
300,566
134,500
Net income
416,121
130.58%
180,470
-48.76%
Dividends
(73,611)
(121,891)
Dividend yield
0.55%
1.91%
Proceeds from repurchase of equity
(196,295)
(147,672)
BB yield
1.46%
2.31%
Debt
Debt current
216,625
34,378
Long-term debt
245,517
145,139
Deferred revenue
13,625
5,500
Other long-term liabilities
5,639
225,853
Net debt
(2,884,958)
(3,026,889)
Cash flow
Cash from operating activities
634,450
231,296
CAPEX
(267,230)
(317,148)
Cash from investing activities
(376,650)
(681,815)
Cash from financing activities
(257,727)
(288,350)
FCF
112,434
(161,271)
Balance
Cash
2,751,082
2,541,715
Long term investments
596,018
664,691
Excess cash
3,215,354
3,101,234
Stockholders' equity
3,267,333
2,931,405
Invested Capital
3,229,152
3,268,507
ROIC
9.25%
3.99%
ROCE
6.00%
2.83%
EV
Common stock shares outstanding
334,261
173,563
Price
40.30
9.36%
36.85
-28.45%
Market cap
13,470,713
110.62%
6,395,788
-29.49%
EV
11,024,429
3,803,693
EBITDA
594,412
384,112
EV/EBITDA
18.55
9.90
Interest
7,295
7,603
Interest/NOPBT
1.84%
4.23%